Bristol-Myers Squibb to use real-world data and artificial intelligence to make sense of clinical studies
Bristol-Myers Squibb (NY, USA) and Concerto HealthAI (MA, USA) have announced a strategic agreement to apply real-world evidence to clinical trials, protocol design and precision medicine.
Bristol-Myers Squibb (NY, USA) and Concerto HealthAI (MA, USA) have entered into a multi-year agreement that will see Concerto’s propriety real-world data (RWD) and artificial intelligence (AI) platform, eurekaHealthâ„¢, being applied to Bristol-Myers Squibbs drug development program. Concerto HealthAI aims to improve outcomes for patients with cancer through integration of AI and real-world evidence (RWE).
“With the increasing importance of RWD and RWE, healthcare providers and regulators need to have confidence in the credibility and accuracy of the data sources and methods of evidence generation,” said Jeff Elton, CEO of Concerto HealthAI.
“Our agreement with Bristol-Myers Squibb is a recognition that we have reached a pivot-point for RWE — it is not just a tool for generating insights into the current standard of care, but a field in its own right that can lead to optimization of current treatments and new therapeutic innovations.”
Concerto HealthAI has integrated data from a range of data sources including CancerLinQ®, which aims to improve understanding and treatment of cancer through collection and analysis of real-time data and is managed by the American Society of Clinical Oncology (VA, USA). The Bristol-Myers Squibb agreement will cover a range of cancers and data sources, and will aim to improve protocol design and clinical trial management, leading to new insight and improved patient outcome.
“At Bristol-Myers Squibb, we have seen the value of Real-World Data in our efforts to discover, develop and deliver medicines for patients,” said Jeff Conklin, Senior Vice President and Head of Business Insights and Analytics at Bristol-Myers Squibb.
“This strategic agreement reinforces our commitment to pursue data science to accelerate disease insights, advance novel study concepts and achieve precision in treatment, with the goal of improving patient outcomes.”